Your browser doesn't support javascript.
loading
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice.
Ciccullo, Arturo; D'Avino, Alessandro; Lassandro, Anna Pia; Baldin, Gianmaria; Borghetti, Alberto; Dusina, Alex; Emiliozzi, Arianna; Gagliardini, Roberta; Moschese, Davide; Belmonti, Simone; Lombardi, Francesca; Di Giambenedetto, Simona.
Afiliação
  • Ciccullo A; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • D'Avino A; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • Lassandro AP; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • Baldin G; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • Borghetti A; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • Dusina A; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • Emiliozzi A; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • Gagliardini R; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • Moschese D; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • Belmonti S; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • Lombardi F; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
  • Di Giambenedetto S; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
Infez Med ; 26(4): 336-340, 2018 Dec 01.
Article em En | MEDLINE | ID: mdl-30555137
ABSTRACT
Bone toxicity is a well-known side effect of several antiviral agents. In a cohort of virologically suppressed HIV-infected patients, we investigated the effects of a lamivudine/dolutegravir dual therapy on bone mineral density (BMD). We observed a significant improvement in lumbar spine BMD as well as T-score after 12 months of observation with concomitant bisphosphonate therapy independently predicting a greater improvement. These preliminary data show a favorable effect of this 2-drug regimen on bone health.
Assuntos
Buscar no Google
Imprimir
XML
PubMed Links

Base de dados: MEDLINE Assunto principal: Densidade Óssea / Infecções por HIV / Inibidores de Integrase de HIV / Lamivudina / Fármacos Anti-HIV / Compostos Heterocíclicos com 3 Anéis Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Buscar no Google
Imprimir
XML
PubMed Links

Base de dados: MEDLINE Assunto principal: Densidade Óssea / Infecções por HIV / Inibidores de Integrase de HIV / Lamivudina / Fármacos Anti-HIV / Compostos Heterocíclicos com 3 Anéis Idioma: En Ano de publicação: 2018 Tipo de documento: Article